Clinical Trial

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Study acronym: TARLANEC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Based on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-14.
Status change: Not Yet Recruiting → Recruiting 2026-02-09
Trial Details
NCT Number NCT06937905
Lead Sponsor Intergroupe Francophone de Cancerologie Thoracique
Conditions Neuroendocrine Carcinoma
Enrollment 129 participants
Start Date 2026-02-06
Primary Completion 2029-02-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-11